New hope for rare lymphoma: mosunetuzumab trial launches
NCT ID NCT06569680
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called mosunetuzumab in 35 people with a rare type of lymphoma (EMZL) who haven't had treatment yet. The drug is given as injections under the skin over several cycles. The goal is to see if it can shrink or eliminate the cancer and to check its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Mosunetuzumab (a drug given as injections under the skin)
- What this could lead to
- If it works, this could offer a new treatment option for people with newly diagnosed extranodal marginal zone lymphoma, potentially improving response rates.
- What could go wrong
- This is a small, early-phase trial (35 people) with no control group. The drug may not work as hoped, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRANODAL MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.